SR One backs B round extension for Dicerna Pharmaceuticals.
Dicerna Pharmaceuticals, a drug development company, has made a second closing of its series B round at $4m with SR One, the corporate venturing division of GlaxoSmithKline, joining as a new investor.
Dicerna previously raised $25m in its B round from venture capital firms Oxford Bioscience Partners, Skyline Ventures, Abingworth and Domain Associates, all of which participated in this round.
Brian Gallagher, a partner at SR One, which has invested about $600m in more than 130 companies since 1985,…
